title: A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
abstract: Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.
authors.affiliation: Cleveland Clinic and Case Western Reserve University,Cleveland, Ohio 44195, USA. tungsim@ccf.org
authors.forename: Marisa
authors.initials: M
authors.lastname: Tungsiripat
authors.forename: Douglas
authors.initials: D
authors.lastname: Kitch
authors.forename: Marshall J
authors.initials: MJ
authors.lastname: Glesby
authors.forename: Samir K
authors.initials: SK
authors.lastname: Gupta
authors.forename: John W
authors.initials: JW
authors.lastname: Mellors
authors.forename: Laura
authors.initials: L
authors.lastname: Moran
authors.forename: Lynne
authors.initials: L
authors.lastname: Jones
authors.forename: Beverly
authors.initials: B
authors.lastname: Alston-Smith
authors.forename: James F
authors.initials: JF
authors.lastname: Rooney
authors.forename: Judith A
authors.initials: JA
authors.lastname: Aberg
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D002784:Cholesterol / Q000097:blood; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004812:Epidemiologic Methods; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D010865:Pilot Projects; D000068698:Tenofovir; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D002784:Cholesterol; D000068698:Tenofovir; D000225:Adenine